Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls

Conditions: Cervical Intraepithelial Neoplasia; Cervical Cancer; Persistent Infection Interventions: Biological: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli); Other: No intervention; Biological: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) Sponsors: Xiamen University; Xiamen Innovax Biotech Co., Ltd; Center for Disease Control and Prevention, Sheyang County, Yancheng City, Jiangsu Province, China Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials